Clinical Trial Update: A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of rifampin on the single-dose pharmacokinetics of BMS-986141 in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• BMS-986141
• RIFAMPIN (RIFAMPIN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Atherothrombotic Diseases | Phase 1 | Status: COMPLETED